MENRIUM 10-4
LOE ApproachingNDAORALTABLET
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MENRIUM 10-4 is an oral tablet NDA approved by Roche in 1966 for an undisclosed indication. The mechanism of action and pharmacologic class are not publicly detailed in available data. This is a legacy small-molecule product with a long commercial history.
LOE Approaching
Approaching loss of exclusivity signals potential team consolidation and shift toward lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product presents a mature-stage career opportunity focused on lifecycle management, cost optimization, and market transition strategy rather than growth. Professionals working on MENRIUM 10-4 should expect focus on profitability defense, generic preparedness, and portfolio optimization.
Brand ManagerCommercial Operations
Worked on MENRIUM 10-4 at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.